190 related articles for article (PubMed ID: 19499255)
1. In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies.
Gallon O; Guillet-Caruba C; Lamy B; Laurent F; Doucet-Populaire F; Decousser JW;
Eur J Clin Microbiol Infect Dis; 2009 Oct; 28(10):1209-15. PubMed ID: 19499255
[TBL] [Abstract][Full Text] [Related]
2. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
[TBL] [Abstract][Full Text] [Related]
3. [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López F; Gómez M;
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):13-6. PubMed ID: 19406529
[TBL] [Abstract][Full Text] [Related]
4. Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia.
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Rodríguez-Vidigal FF; Vera Tomé A; Robles Marcos M
Rev Esp Quimioter; 2011 Jun; 24(2):74-8. PubMed ID: 21666998
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
6. Serious staphylococcal infections--cyclic lipopeptides: meeting new challenges.
Graninger W
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():1-2. PubMed ID: 18226083
[No Abstract] [Full Text] [Related]
7. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
Sader HS; Farrell DJ; Jones RN
J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients.
Kratzer C; Rabitsch W; Hirschl AM; Graninger W; Presterl E
Eur J Haematol; 2007 Nov; 79(5):405-9. PubMed ID: 17714506
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin heteroresistance in coagulase negative Staphylococcus blood stream infections from patients of intensive care units in Mansoura University Hospitals, Egypt.
Mashaly GE; El-Mahdy RH
Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):63. PubMed ID: 28927452
[TBL] [Abstract][Full Text] [Related]
10.
Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
[No Abstract] [Full Text] [Related]
11. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides.
Del' Alamo L; Cereda RF; Tosin I; Miranda EA; Sader HS
Diagn Microbiol Infect Dis; 1999 Jul; 34(3):185-91. PubMed ID: 10403098
[TBL] [Abstract][Full Text] [Related]
12. Treatment of staphylococcal infections with cyclic lipopeptides.
Eisenstein BI
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():10-6. PubMed ID: 18226085
[TBL] [Abstract][Full Text] [Related]
13. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance.
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López-Fabal F; Gómez M;
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):373-9. PubMed ID: 21683269
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
15. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers.
Picazo JJ; Betriu C; Culebras E; Rodríguez-Avial I; Gómez M; López F;
Diagn Microbiol Infect Dis; 2009 Aug; 64(4):448-51. PubMed ID: 19631100
[TBL] [Abstract][Full Text] [Related]
16. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
17. [In vitro effect of vancomycin and daptomycin on biofilm formation of coagulase-negative staphylococci strains].
Öcal DN; Dolapçı İ; Gençtürk Z; Tekeli A
Mikrobiyol Bul; 2017 Jul; 51(3):220-235. PubMed ID: 28929959
[TBL] [Abstract][Full Text] [Related]
18. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
[TBL] [Abstract][Full Text] [Related]
19. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.
Quist SR; Fierlbeck G; Seaton RA; Loeffler J; Chaves RL
Int J Antimicrob Agents; 2012 Jan; 39(1):90-1. PubMed ID: 21982144
[No Abstract] [Full Text] [Related]
20. Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada.
Pfaller MA; Castanheira M; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Mar; 35(3):282-7. PubMed ID: 20036520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
